MORPHOSYS AG - AMERICAN DEPOSITARY SHARES
MORPHOSYS AG - AMERICAN DEPOSITARY SHARES
Hinterlegungsschein · US6177602025 · MOR · A2JJ5S (XNAS)
Übersicht
Kein Kurs
n/a

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
- - - - 0,00 % 4,35 % -37,69 %

Firmenprofil zu MORPHOSYS AG - AMERICAN DEPOSITARY SHARES Hinterlegungsschein

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Unternehmensdaten

Name MORPHOSYS AG - AMERICAN DEPOSITARY SHARES
Firma MorphoSys AG
Symbol MOR
Website https://www.morphosys.com
Heimatbörse XNAS NASDAQ
WKN A2JJ5S
ISIN US6177602025
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Mr. Arkadius Pichota M.B.A., Ph.D.
Marktkapitalisierung 3 Mrd.
Land Deutschland
Währung USD
Mitarbeiter 0,5 T
Adresse Semmelweisstrasse 7, 82152 Planegg
IPO Datum 2018-04-19

Ticker Symbole

Name Symbol
Frankfurt MOR2.F
NASDAQ MOR

Weitere Aktien

Investoren die MORPHOSYS AG - AMERICAN DEPOSITARY SHARES die halten, haben auch folgende Aktien im Depot:
INVESTEC BANK PLC KICK OUT NTS CAP 06/06/22
INVESTEC BANK PLC KICK OUT NTS CAP 06/06/22 Anleihe
STE GENERALE 18/28FLR MTN
STE GENERALE 18/28FLR MTN Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025